Kwality Pharmaceuticals Ltd
₹3528.40
-89.90 (2.48%)
Sun, 25 Oct 2026, 02:24 pm
Health Technology
Pharmaceuticals: Major
24.5KKwality Pharmaceuticals Ratios
| Particulars | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Price to earnings ratio | 0 | 0 | 0 | 0 | 0 | 0 | 14.66 | 9.36 | 5.09 | 3.19 | 3.84 | 5.02 | 16.47 | 17.85 | 22.63 |
| Price to book ratio | 0 | 0 | 0 | 0 | 0 | 0 | 1.95 | 1.43 | 1.03 | 0.58 | 0.95 | 3.32 | 1.59 | 1.89 | 3.42 |
| Price to sales ratio | 0 | 0 | 0 | 0 | 0 | 0 | 0.50 | 0.31 | 0.23 | 0.19 | 0.22 | 1.32 | 1.27 | 1.38 | 2.44 |
| Price to cash flow ratio | 0 | 0 | 0 | 0 | 0 | 0 | 13.43 | 0 | 3.56 | 8.30 | 2.30 | 9.76 | 7.69 | 13.15 | 21.45 |
| Enterprise value | 0 | 0 | 0 | 0 | 0 | 0 | 61.84Cr | 61.68Cr | 60.76Cr | 55.56Cr | 87.79Cr | 642Cr | 401Cr | 515Cr | 998Cr |
| Enterprise value to EBITDA ratio | 0 | 0 | 0 | 0 | 0 | 0 | 6.34 | 5.22 | 3.84 | 3.19 | 2.88 | 3.70 | 6.35 | 7.40 | 11.97 |
| Debt to equity ratio | 1.59 | 0.91 | 0.51 | 0.32 | 0.42 | 0.59 | 0.74 | 0.89 | 0.77 | 0.76 | 0.67 | 0.30 | 0.45 | 0.44 | 0.43 |
| Return on equity % | 0 | 7.07 | 10.46 | 6.31 | 4.36 | 7.69 | 14.21 | 16.43 | 22.53 | 19.97 | 28.27 | 99.05 | 10.15 | 11.21 | 16.32 |
Kwality Pharmaceuticals Ltd Ratios
The Kwality Pharmaceuticals Ltd Ratios page provides a complete fundamental analysis of Kwality Pharmaceuticals Ltd using key valuation, profitability, and financial strength metrics. Investors tracking Kwality Pharmaceuticals Ltd Ratios closely monitor D/E, EV, EV/EBITDA, P/B, P/CF, P/E, P/S, and ROE% to evaluate the company's financial performance and valuation trends over time.
Kwality Pharmaceuticals Ltd (NSE: , BSE: 539997) is currently trading at ₹3528.40, with a market capitalization of ₹3664.56Cr. As a major player in the Health technology sector and Pharmaceuticals: major industry, Kwality Pharmaceuticals Ltd remains a key stock for fundamental analysis using Kwality Pharmaceuticals Ltd Ratios.
Kwality Pharmaceuticals Ltd Ratios: Valuation Overview
Price to Earnings Ratio (P/E)
The Kwality Pharmaceuticals Ltd P/E ratio currently stands at 22.63, making it one of the most tracked metrics in Kwality Pharmaceuticals Ltd Ratios.
Historically, the Kwality Pharmaceuticals Ltd P/E ratio has shown strong fluctuations:
- 2025: 22.63
- 2024: 17.85
- 2023: 16.47
- 2022: 5.02
- 2021: 3.84
The rising Kwality Pharmaceuticals Ltd P/E ratio indicates increasing investor confidence and premium valuation.
Price to Book Ratio (P/B)
The Kwality Pharmaceuticals Ltd P/B ratio reflects how the market values the company's net assets. Current P/B ratio is 3.42.
Historical P/B trend:
- 2025: 3.42
- 2024: 1.89
- 2023: 1.59
- 2022: 3.32
Kwality Pharmaceuticals Ltd is trading at a premium to its book value, indicating strong market confidence.
Price to Sales Ratio (P/S)
The Kwality Pharmaceuticals Ltd P/S ratio currently stands at 2.44, an important part of Kwality Pharmaceuticals Ltd Ratios for revenue valuation.
Historical P/S ratio:
- 2025: 2.44
- 2024: 1.38
- 2023: 1.27
- 2022: 1.32
The rising Kwality Pharmaceuticals Ltd P/S ratio indicates improved revenue valuation by investors.
Kwality Pharmaceuticals Ltd Price to Cash Flow Ratio (P/CF)
The Kwality Pharmaceuticals Ltd Price to Cash Flow Ratio is a key valuation metric that shows how much investors pay for each unit of cash flow. Current P/CF ratio is 21.45.
Historical Kwality Pharmaceuticals Ltd Price to Cash Flow Ratio:
- 2025: 21.45
- 2024: 13.15
- 2023: 7.69
- 2022: 9.76
- 2021: 2.30
The rising Kwality Pharmaceuticals Ltd Price to Cash Flow Ratio indicates premium valuation based on cash flow.
Kwality Pharmaceuticals Ltd Enterprise Value Ratios
Enterprise Value (EV)
The Kwality Pharmaceuticals Ltd EV currently stands at ₹998Cr, representing the total company valuation including debt.
Historical EV trend:
- 2025: 998Cr
- 2024: 515Cr
- 2023: 401Cr
- 2022: 642Cr
Kwality Pharmaceuticals Ltd enterprise value shows long-term growth, reflecting expansion and market confidence.
EV/EBITDA Ratio
The Kwality Pharmaceuticals Ltd EV/EBITDA ratio is currently 11.97, a key metric in Kwality Pharmaceuticals Ltd Ratios to assess valuation relative to earnings.
Historical EV/EBITDA:
- 2025: 11.97
- 2024: 7.40
- 2023: 6.35
- 2022: 3.70
Higher Kwality Pharmaceuticals Ltd EV/EBITDA suggests premium valuation.
Kwality Pharmaceuticals Ltd Financial Strength Ratios
Debt to Equity Ratio (D/E)
The Kwality Pharmaceuticals Ltd D/E ratio is currently 0.43, reflecting leverage and financial stability.
Historical D/E:
- 2025: 0.43
- 2024: 0.44
- 2023: 0.45
- 2022: 0.30
Kwality Pharmaceuticals Ltd maintains a strong balance sheet with low debt levels.
Return on Equity (ROE %)
The Kwality Pharmaceuticals Ltd ROE currently stands at 16.32%, showing profitability and capital efficiency.
Historical ROE:
- 2025: 16.32
- 2024: 11.21
- 2023: 10.15
- 2022: 99.05
Kwality Pharmaceuticals Ltd maintains stable profitability levels.
Kwality Pharmaceuticals Ltd Ratios Analysis Summary
The Kwality Pharmaceuticals Ltd Ratios page provides a comprehensive view of the company's valuation and financial performance. Key metrics such as P/E, P/B, P/S, P/CF, EV, EV/EBITDA, D/E, and ROE help investors understand whether Kwality Pharmaceuticals Ltd stock is undervalued, fairly valued, or overvalued.
Tracking Kwality Pharmaceuticals Ltd Ratios regularly helps investors make informed decisions based on valuation trends, financial stability, and long-term growth potential.
